Speaking of Northern United Pharmaceutical, there is still some value. ranwen

Tens of thousands of acres of land have just been acquired. For the time being, the tens of thousands of skilled workers can't be regarded as a burden, but they are all skilled workers.

However, the reality is that there was no shortage of skilled workers in China in the 1980s. So many small, third-tier, large, and third-tier workers will lose their jobs. If it weren’t for the establishment of the Chemical Drug Promotion Office and Northern United Pharmaceutical, the 10,000 workers in North China Pharmaceutical would face unemployment within a few years.

To be more precise, tens of thousands of workers are mixed together, like a pile of unsorted jujubes, if the stalls are not scattered, the bad jujubes will sooner or later take away the good ones.

No one expected that such a Northern United Pharmaceutical Co., Ltd. could value 60 million U.S. dollars and then collect real money from Zelecom.

Regarding Zelekang, whether it is Northern United Pharmaceuticals or the Chemical Drug Promotion Office, they are not interested. The only thing they are interested in is the medicines in Yang Rui's hands.

Only the profits from production and sales can make them earn back their capital.

Only the new drugs developed by Yang Rui can make them back 30 million U.S. dollars.

The desire of pharmaceutical companies for new drugs is difficult for workers in other industries to appreciate.

There are thousands of pharmaceutical companies around the world, and the number of pharmaceutical companies capable of developing new drugs is usually within a hundred. Except for single-digit generic drug companies, the remaining double-digit pharmaceutical companies can only enter the market three times a year. Five pure new medicines.

At this time, whoever holds the new medicine is almost in control of life and death.

Not in a symbolic sense, but actually the power of life and death.

For example, Gaucher disease. Although it is a rare disease, it is also a rare disease with a high incidence. There are hundreds of thousands of patients in the world. However, in the absence of suitable medicines, the life cycle of Gaucher patients Since the onset of disease, it is only 10 years, basically not more than 20 years.

At this time, there is also a message that no one wants to think about. If there are really special medicines, there will not be only hundreds of thousands of Gaucher patients in the world.

With so many people, it is obviously impossible to get medicines at once.

Even from a safety perspective, countries will not allow new drugs to be rolled out in their homes at once.

At this time, the pharmaceutical company actually controls the life and death of these Gaucher patients.

In which country they apply for sales first, Gaucher patients in which country can receive treatment in advance. This not only means a higher survival rate, but also means reducing pain and improving the quality of life.

No one wants to drag a sick body to live.

From the perspective of consumers and hospitals, they also expect the emergence of specific drugs.

Pharmaceutical companies that can always produce new and good medicines will be more popular with hospitals and doctors. This is a force unique to pharmaceutical companies. When necessary, pharmaceutical companies can even carry out bundling sales, stipulating that as many special medicines are purchased, as many ordinary medicines must be purchased...

In places where laws and regulations are not strict, whoever holds the power of life and death is entitled to make money.

How much are 500,000 lives worth?

Isn't it more than $100 per person?

Is 200 dollars expensive for a person?

In the modern consumption system, production costs are only small for pharmaceutical companies, and sales, R&D, and management costs are the most expensive places.

A new drug may not be able to make a pharmaceutical company rich in one go. After all, blockbusters with annual sales of 1 billion US dollars are a minority. However, a steady stream of new drugs is the survival meaning of the pharmaceutical company.

It is not only the significance of the survival of the pharmaceutical company itself, but also the perception of the public, society and the country.

If a pharmaceutical company cannot produce a new drug in five years, regardless of whether it is made or bought, even if it makes a lot of other income, investors will always be worried about it.

If a pharmaceutical company cannot produce a new drug in 10 years, even if the investor does not say it, the company will not be able to sustain it.

In an industry that sells health and life, pharmaceutical companies have too many ways to make money.

For some special rare drugs, the annual treatment cost can even reach millions of dollars, which can be called abnormal. Pharmaceutical companies in war-torn areas have never appeared benevolent. Pharmaceutical companies in prosperous cities are even more adept at doing fly-by-play activities.

However, no matter how the pharmaceutical company wants to make money, you must first have the medicine in your hands.

New drugs with a 15-year patent period and orphan drugs with a 25-year patent period are weapons in the hands of pharmaceutical companies.

As much as a 15-year-old boy is willing to pay for his Rogue weapon, the pharmaceutical company is willing to pay for a new drug.

The careful thinking of Northern United Pharmaceutical, under the pressure of Zelican, like ice and snow falling on the oven, disappeared without a trace in a moment.

However, the funds allocated to the account of the ion channel laboratory in advance are still only a pitiful $200,000.

In the words of Comrade Wang Gaohan, the new general manager of Beifang United Pharmaceutical: "If you use it first, if it is not enough, say hello, and the money will come."

The project team responsible for the reorganization of DNA was naturally complaining, and Gu Qiang even complained: “The US$200,000 is not enough to buy a fluorescence microplate reader. It is over without starting.”

Yang Rui's choice for Gaucher's disease is an enzyme replacement program. It is a simple principle for people who lack enzymes to supplement enzymes.

However, it is extremely difficult to make glucocerebrosidase suitable for the human body and no matter how this step is performed, an instrument such as a fluorescence microplate reader is a must.

Glucocerebrosidase is invisible to the human eye.

In addition, ~lightnovelpub.net~ a higher resolution UV-Vis spectrophotometer, a new type of electrophoresis instrument with higher efficiency, etc., are also indispensable expenses.

Although laboratories can share these commonly used equipment, it is obviously not the right choice to grab the instrument in the tight time of new drug development.

In addition, the scale of ion channel laboratories is expanding day by day, and new instruments must be added to open up new projects, even if it is repeated instruments, it is inevitable. It's like the simplest microscope. There can't be a group of lab dogs waiting in line for use.

There are some domestic project teams who are very poor and poor. Yang Rui is not going to let the ion channel laboratory go through the hard days of queuing up for instruments at two o'clock in the morning.

Who loves who is in the past.

"Take the money from the laboratory's general ledger, and give them back 200,000 US dollars." Yang Rui quickly made a decision, and then called Xu Zhengping, said: "You can contact a foreign evaluation company to discuss our current reorganization. The dna project team conducted a price evaluation of the alternative plan for glucocerebrosidase."

"What's that?" Xu Zhengping was quite taken aback.

"Just find a foreigner's company to come over and let them see how much the things our project team makes are worth in the market." Yang Rui paused, and said, "People from Northern United Pharmaceutical are used to living as a state-owned enterprise. Thinking about the cost price to get the research results. 200,000? 2 million will buy a head."

Xu Zhengping hesitated to look for it. He still didn't know how strong Yang Rui's decision was to oppress Northern United Pharmaceutical. In fact, there are basically no domestic companies that can appreciate this.

In this era when companies have institutes, the value of research results has always been floated at cost.

Unfortunately, Yang Rui is not prepared to discuss cost issues with them.

The cost is my business, and the price is determined by the value.